- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 5, 2024Jake Holdreith Named to Twin Cities Business Top 100
-
December 4, 2024Robins Kaplan Obtains $10.5 Million Post-Verdict in Landmark Aerosol Dust Remover Abuse Case
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
GENERICally Speaking Fall 2021
Fall 2021
The Fall 2021 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
In this issue:
- Belcher Pharms., LLC v. Hospira, Inc.
Epinephrine
Federal Circuit affirms finding of unenforceability on the basis of inequitable conduct where plaintiff’s employee—involved in regulatory application and patent prosecution—made inconsistent statements to FDA and PTO Examiner regarding claimed pH range. - GlaxoSmithKline LLC v. Teva Pharms. USA, Inc.
Coreg® (carvedilol)
Appeals court vacated JMOL of non-infringement based on section section viii carve out, reinstated jury’s damages award, and remanded for further proceedings. - Sun Pharma Global FZE v. Lupin Ltd.
Bromsite® (bromfenac ophthalmic solution)
The patent in suit is not infringed and invalid as obvious and indefinite, but not unenforceable on the basis of inequitable conduct. - Par Pharmaceutical Inc. v. Eagle Pharmaceuticals Inc.
Vasostrict® (vasopressin)
Because the ANDA controlled when it came to the issue of infringement, the pH range of the ANDA product fell outside of the claimed pH range, thereby justifying the court’s non-infringement finding. - Pharmacyclics LLC v. Alvogen Pine Brook LLC
Imbruvica® (ibrutinib)
Defendant did not meet its burden in proving that the four patents-in-suit were invalid on the basis of anticipation, obviousness, and lacking adequate written description. - Amarin Pharma, Inc. v. Hikma Pharms. USA Inc.
Vascepa® (icosapent ethyl)
The court recommended denying a motion to dismiss for lack of causation, finding that patentee plausibly pled a novel theory of induced infringement against a health insurance provider who actively encouraged the use of a generic drug through its approval and payment process. - Takeda Pharma Co. v. Zydus Pharma Inc.
Prevacid® SoluTab™
After filing competing summary judgment motions, the court granted plaintiff’s motion and denied defendant’s motion, finding that the underlying patent infringement suit was not a sham litigation. - Almirall, LLC v. Torrent Pharms., Ltd.
Aczone® Gel, 7.5% (Dapsone)
Defendant’s motion pursuant to Fed. R. Civ. P. 12(c) for judgment of non-infringement on the pleadings granted. - Auxilium Pharms., Inc. v. FCB I LLC
Testim® (testosterone gel)
The court denied plaintiff’s motion for a default judgment because the complaint did not include a sufficiently pled cause of action.
Relevant ANDA Updates highlighted in this issue:
New Drug Applications and 505(b)(2) Applications
Reported settlements in federal district court cases
Abbreviated New Drug Applications and 505(b)(2) Applications
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Epinephrine
Vasostrict® (vasopressin)
Imbruvica® (ibrutinib)
Bromsite® (bromfenac ophthalmic solution)
Coreg® (carvedilol)
Vascepa® (icosapent ethyl)
Prevacid® SoluTab™ (lansoprazole delayed-release orally-disintegrating tablets)
Aczone® Gel, 7.5% (Dapsone)
Testim® (testosterone gel)
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.